Gastrointestinal Diseases Research Unit, Kingston General Hospital, Queen's University, Kingston, ON, Canada.
Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13238. Epub 2017 Nov 2.
Functional gastrointestinal symptoms in irritable bowel syndrome (IBS) and quiescent inflammatory bowel disease (IBD) cause significant morbidity and a reduction in quality of life. Multiple dietary therapies are now available to treat these symptoms, but supporting evidence for many is limited. In addition to a further need for studies demonstrating efficacy and mechanism of action of dietary therapies, the risk of nutritional inadequacy, alterations to the microbiome and changes in quality of life are key concerns requiring elucidation. Identifying predictors of response to dietary therapy is an important goal as management could be tailored to the individual to target specific dietary components, and thereby reduce the level of dietary restriction necessary.
This review discusses the available dietary therapies to treat symptoms in patients with IBS and patients with quiescent IBD suffering from IBS symptoms, with the aim to understand where current dietary evidence lies and how to move forward in dietary research in this field.
肠易激综合征（IBS）和静止期炎症性肠病（IBD）患者的功能性胃肠道症状会导致较高的发病率和生活质量下降。目前有多种饮食疗法可用于治疗这些症状，但许多疗法的支持证据有限。除了需要更多研究来证明饮食疗法的疗效和作用机制外，营养不足、微生物组改变和生活质量变化的风险是需要阐明的关键问题。确定对饮食疗法的反应预测因素是一个重要目标，因为可以根据个体情况调整管理方法，针对特定的饮食成分，从而减少所需的饮食限制水平。
本文讨论了现有的饮食疗法，以治疗 IBS 患者和患有静止期 IBD 且伴有 IBS 症状患者的症状，旨在了解当前饮食证据的现状，并探讨如何在该领域的饮食研究中取得进展。
